These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21323509)

  • 1. Glutathione peroxidase activity in the blood cells of psoriatic patients correlates with their responsiveness to Efalizumab.
    Pastore S; Mariani V; Lulli D; Gubinelli E; Raskovic D; Mariani S; Stancato A; de Luca C; Pecorelli A; Valacchi G; Potapovich AI; Kostyuk VA; Korkina LG
    Free Radic Res; 2011 May; 45(5):585-99. PubMed ID: 21323509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
    Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
    JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topo-proteomic in situ analysis of psoriatic plaque under efalizumab treatment.
    Bonnekoh B; Pommer AJ; Böckelmann R; Hofmeister H; Philipsen L; Gollnick H
    Skin Pharmacol Physiol; 2007; 20(5):237-52. PubMed ID: 17587888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
    Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
    Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CD11a binding site of efalizumab in psoriatic skin tissue as analyzed by Multi-Epitope Ligand Cartography robot technology. Introduction of a novel biological drug-binding biochip assay.
    Bonnekoh B; Böckelmann R; Pommer AJ; Malykh Y; Philipsen L; Gollnick H
    Skin Pharmacol Physiol; 2007; 20(2):96-111. PubMed ID: 17167274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efalizumab.
    Talamonti M; Spallone G; Di Stefani A; Costanzo A; Chimenti S
    Expert Opin Drug Saf; 2011 Mar; 10(2):239-51. PubMed ID: 21214420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of compartmentalization of T-cell subsets for clinical improvement in psoriasis: effect of immune-targeted antipsoriatic therapies.
    van Lingen RG; Körver JE; van de Kerkhof PC; Berends MA; van Rens DW; Langewouters AM; Boezeman JB; Seyger MM; de Jong EM
    Br J Dermatol; 2008 Jul; 159(1):91-6. PubMed ID: 18476954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.
    Costanzo A; Talamonti M; Botti E; Spallone G; Papoutsaki M; Chimenti S
    Dermatology; 2009; 219(1):48-53. PubMed ID: 19372639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A; Kosinski M; Bresnahan BW; Papp KA; Ware JE
    J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efalizumab, a reversible T-cell modulator for psoriasis.
    Shear NH; Langley RG; Ho V
    J Cutan Med Surg; 2006; 9 Suppl 1():4-9. PubMed ID: 16633862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital.
    Antoniou C; Stefanaki I; Stratigos A; Avgerinou G; Stavropoulos P; Potouridou I; Polidorou D; Moustou AE; Kosmadaki M; Katsambas AD
    Br J Dermatol; 2007 Apr; 156 Suppl 2():12-6. PubMed ID: 17371318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis.
    Ng CM; Joshi A; Dedrick RL; Garovoy MR; Bauer RJ
    Pharm Res; 2005 Jul; 22(7):1088-100. PubMed ID: 16028009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
    Lebwohl M; Tyring SK; Hamilton TK; Toth D; Glazer S; Tawfik NH; Walicke P; Dummer W; Wang X; Garovoy MR; Pariser D;
    N Engl J Med; 2003 Nov; 349(21):2004-13. PubMed ID: 14627785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness.
    Guttman-Yassky E; Vugmeyster Y; Lowes MA; Chamian F; Kikuchi T; Kagen M; Gilleaudeau P; Lee E; Hunte B; Howell K; Dummer W; Bodary SC; Krueger JG
    J Invest Dermatol; 2008 May; 128(5):1182-91. PubMed ID: 18239614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience.
    Langley RG; Carey WP; Rafal ES; Tyring SK; Caro I; Wang X; Wetherill G; Gordon KB
    Clin Ther; 2005 Sep; 27(9):1317-28. PubMed ID: 16291408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis.
    Viguier M; Richette P; Aubin F; Beylot-Barry M; Lahfa M; Bedane C; Delesalle F; Richard-Lallemand MA; Delaporte E; Dubertret L; Bardin T; Bachelez H
    Arthritis Rheum; 2008 Jun; 58(6):1796-802. PubMed ID: 18512820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efalizumab-induced guttate psoriasis. Successful management and re-treatment.
    Balato A; La Bella S; Gaudiello F; Balato N
    J Dermatolog Treat; 2008; 19(3):182-4. PubMed ID: 18569275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efalizumab treatment of psoriasis vulgaris: a cohort study in outpatient clinical practice.
    Puig L; Roé E; García-Navarro X; Corella F; Alomar A
    Clin Exp Dermatol; 2009 Jun; 34(4):469-75. PubMed ID: 19077105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
    Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
    Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.